Understanding GLP-1 and GIP/GLP-1 Medications

Medications that act on GLP-1 pathways have become an important topic in metabolic care. Semaglutide is a GLP-1 receptor agonist, while tirzepatide acts on both GIP and GLP-1 receptors. Although these medications share some features, they are not interchangeable, and each has its own approved indications, dosing instructions, safety information, and clinical considerations.

Understanding the basics can make conversations with a healthcare professional more productive.

What is GLP-1?

GLP-1, or glucagon-like peptide-1, is a hormone released by the digestive system after eating. It participates in several normal processes, including:

• Glucose-dependent insulin signaling

• Glucagon regulation

• Digestion and gastric emptying

• Appetite and satiety signaling

GLP-1 receptor agonists are medications designed to act on the same receptor. Their effects are longer lasting than those of naturally occurring GLP-1.

How is tirzepatide different?

Tirzepatide acts on two receptors: GIP and GLP-1. GIP stands for glucose-dependent insulinotropic polypeptide, another hormone involved in the body's response to food.

Acting on two receptors does not automatically make a medication appropriate for every person. A clinician considers the medication's specific indication, health history, current medications, contraindications, treatment goals, and potential risks.

Why are these medications introduced gradually?

Clinicians commonly use a stepwise dosing schedule to evaluate tolerability. Gastrointestinal effects can occur, particularly when treatment begins or the dose changes.

Commonly reported effects include:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Abdominal discomfort

• Reduced appetite

A prescribed dose should not be increased, decreased, or taken more frequently without guidance from the prescribing clinician.

What does responsible monitoring involve?

Medication is only one part of a treatment plan. Follow-up care may include discussion of:

• Side effects and tolerability

• Nutrition and hydration

• Changes in appetite or eating patterns

• Physical activity

• Other medications

• Relevant laboratory results

• Whether the current plan remains appropriate

The purpose of follow-up is not simply to increase a dose. In some situations, maintaining, reducing, pausing, or discontinuing treatment may be more appropriate.

Who should have a more detailed safety conversation?

Every patient needs an individualized review. It is especially important to tell a clinician about pregnancy or pregnancy plans, severe digestive conditions, gallbladder or pancreatic problems, kidney concerns, diabetes medications, and any personal or family history relevant to the medication's boxed warning or contraindications.

Patients should read the medication guide supplied with an FDA-approved product. When a compounded medication is prescribed, the dispensing pharmacy's label and instructions are also essential.

FDA-approved and compounded medications are not the same

An FDA-approved medication has been reviewed by the agency for safety, effectiveness, manufacturing quality, and labeling for its approved use. A compounded drug is prepared for an individual patient under applicable compounding rules and is not FDA approved.

Compounding can have a role in patient care, but compounded products should not be described as generic versions of branded medications or as having undergone FDA approval. Concentration, container, inactive ingredients, storage requirements, and beyond-use dates may differ.

Questions to ask a clinician

• What is the intended role of this medication in my care plan?

• Is the product FDA approved or compounded?

• What dose and concentration am I receiving?

• How should I store and administer it?

• Which side effects should prompt a routine call?

• Which symptoms require urgent medical attention?

• How will we evaluate whether the plan remains appropriate?

• Could this medication interact with my other prescriptions?

Key takeaway

GLP-1 and dual GIP/GLP-1 medications are prescription treatments that require individualized clinical decision-making. Online discussions can provide general awareness, but they cannot determine whether a medication, formulation, or dose is appropriate for a particular person.

FAQ

Are semaglutide and tirzepatide the same medication?
No. Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at both GIP and GLP-1 receptors. They have separate prescribing information and should not be substituted without clinician direction.

Does everyone follow the same dosing schedule?
No. Product labeling provides standard schedules for FDA-approved products, but individual prescribing decisions may differ based on indication, tolerability, medical history, and formulation.

Are side effects guaranteed?
No. Some people experience side effects and others do not. Their type and severity vary.

Does medication replace nutrition and activity habits?
No. When these medications are used for chronic weight management, they are generally part of a broader plan that includes nutrition, physical activity, and ongoing clinical care.

Medical disclaimer

This article is for general education only and does not diagnose, treat, cure, or prevent any condition. It is not a substitute for individualized medical advice. Seek prompt medical care for severe or concerning symptoms.

Sources

• U.S. Food and Drug Administration, prescribing information for semaglutide products

• U.S. Food and Drug Administration, prescribing information for tirzepatide products

• National Institute of Diabetes and Digestive and Kidney Diseases, “Prescription Medications to Treat Overweight & Obesity”

• U.S. Food and Drug Administration, information for consumers about compounded drugs